8-KEarnings & ResultsLeadership ChangesOther Events+1

DEXCOM INC 8-K Report, Financial Results (May 3, 2011)

Filed May 3, 2011For Securities:DXCM

Summary

DexCom, Inc. (DXCM) filed an 8-K on May 3, 2011, primarily to report on its Q1 2011 financial results and key leadership changes. While the specific Q1 2011 financial performance details are available in an attached press release (Exhibit 99.01), the filing highlights significant executive and board-level appointments. Investors should note the appointment of Kevin Sayer as President, effective June 1, 2011. Mr. Sayer brings substantial experience in the medical technology sector, including previous roles at Biosensors International and Medtronic MiniMed, and has been a Class I director at DexCom since November 2007. His compensation package includes a base salary, potential bonus, and a significant restricted stock unit grant, reflecting his new executive role. Additionally, the board has been expanded, with Barbara Kahn and Martin Doordan elected as Class II directors, bringing new expertise to the company and filling committee vacancies.

Key Highlights

  • 1DexCom announced its financial results for the quarter ended March 31, 2011, via a press release filed as an exhibit.
  • 2Kevin Sayer, currently a Class I director, has been appointed as the new President of DexCom, effective June 1, 2011.
  • 3Mr. Sayer has a strong background in medical technology, including previous roles at Biosensors International and Medtronic MiniMed.
  • 4Kevin Sayer's compensation package includes a $300,000 base salary, a target annual bonus of 90% of base salary, and a restricted stock unit grant valued at $1.5 million, vesting over three years.
  • 5The Board of Directors was expanded to eight members.
  • 6Barbara Kahn and Martin Doordan were elected as Class II directors to fill vacancies.
  • 7Committee reassignments were made following the board expansion and new presidential appointment, including to the Audit, Compensation, and Nominating and Governance Committees.

Frequently Asked Questions

The 8-K filing refers to a press release (Exhibit 99.01) dated May 3, 2011, which contains the detailed financial results for the quarter ended March 31, 2011. Investors would need to refer to that specific exhibit for the quantitative financial performance data.

Kevin Sayer's appointment as President brings a seasoned executive with extensive experience in the medical technology industry to a key leadership role. His prior roles, including CFO of Biosensors International and executive positions at Medtronic MiniMed, suggest a focus on operational and financial management critical for a growing company in the diabetes technology sector. His prior directorship also indicates familiarity with DexCom's strategic direction.

Kevin Sayer will receive an annual base salary of $300,000, be eligible for an annual cash bonus with a target of 90% of his base salary, and has been granted restricted stock units (RSUs) valued at $1,500,000. These RSUs will vest over three years, with initial vesting after one year and subsequent installments every six months thereafter. He will also be eligible for severance benefits under the company's standard executive agreement.

Barbara Kahn and Martin Doordan have been elected as Class II directors, expanding the board to eight members. Their election, along with committee reassignments, indicates a strengthening of the board's oversight and governance structure. While their specific experience is not detailed in the 8-K beyond their compensation being consistent with existing policies, their addition suggests a continued focus on robust board composition.